
scPharmaceuticals Inc. (NASDAQ:SCPH) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) of the drug candidate FUROSCIX, for the treatment of congestion in patients with worsening heart failure.
The regulatory agency has set target action date of October 8, 2022